Jefferies Financial Group Inc. Acquires New Shares in BioNTech SE (NASDAQ:BNTX)

Jefferies Financial Group Inc. acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,000 shares of the company’s stock, valued at approximately $570,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Deutsche Bank AG raised its holdings in shares of BioNTech by 2.3% in the fourth quarter. Deutsche Bank AG now owns 304,500 shares of the company’s stock valued at $34,698,000 after acquiring an additional 6,749 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of BioNTech by 632.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company’s stock valued at $57,191,000 after acquiring an additional 433,388 shares in the last quarter. Crestline Management LP bought a new stake in shares of BioNTech in the fourth quarter valued at about $943,000. Braidwell LP raised its holdings in shares of BioNTech by 25.1% in the fourth quarter. Braidwell LP now owns 309,865 shares of the company’s stock valued at $35,309,000 after acquiring an additional 62,115 shares in the last quarter. Finally, Bridgefront Capital LLC bought a new stake in shares of BioNTech in the fourth quarter valued at about $284,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

Shares of BNTX stock opened at $92.77 on Friday. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a market capitalization of $22.30 billion, a price-to-earnings ratio of -44.18 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock’s 50-day simple moving average is $97.41 and its 200-day simple moving average is $108.88.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The company’s revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts forecast that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BNTX shares. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Citigroup reiterated a “buy” rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Morgan Stanley cut their target price on BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $134.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $142.08.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.